The Athinoula A Martinos Center for Biomedical Imaging at Massachusetts General Hospital selects Cubresa’s BrainPET Insert System to Support Brain Research Studies

The Martinos Center has selected Cubresa’s investigational BrainPET System to add to their suite of imaging tools.

The Cubresa BrainPET Insert System will benefit the research efforts of ongoing projects focused on several neurological disorders and related topics including, anxiety disorders, autism spectrum disorder, bipolar disorder, depression, HIV/AIDS and mental health, schizophrenia, substance use, traumatic events, as well as neurological diseases and basic neuroscience.

“Simultaneous acquisition of magnetic resonance (MR) and positron emission tomography (PET) images can provide unparalleled insights into the brain,” said Dr. Ciprian Catana, Director of Integrated MR-PET Imaging at the MGH Martinos Center for Biomedical Imaging and Associate Professor in Radiology at Harvard Medical School. “We expect this unique MR-compatible head-only PET insert to advance a range of ongoing studies of neurological disorders, for example, while fostering opportunities for new projects and collaborations.”

“Dr. Catana and his colleagues are world leaders in integrated PET/MRI research”, said Dr. James Schellenberg, Cubresa’s Founder and CEO. “We are extremely pleased to have them join our Foundational Client Program and have Cubresa’s BrainPET support their vast brain research activities. We look forward to working with them over the coming years.”

Cubresa’s Foundational Client Program is designed for world-leading, innovative brain research institutions who are seeking to enhance their brain-focused research activities with the addition of a novel BrainPET system, enabling simultaneous PET/MR imaging.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”